ptk787 + verteporfin

**PTK787 + verteporfin** is an experimental combination therapy consisting of PTK787 (vatalanib), an oral inhibitor of vascular endothelial growth factor receptors (VEGFRs), and verteporfin, a photosensitizer used in photodynamic therapy (PDT) primarily for choroidal neovascularization secondary to conditions like age-related macular degeneration (AMD). PTK787 acts as an anti-angiogenic agent by inhibiting VEGFR-mediated signaling, aiming to reduce abnormal blood vessel growth and leakage. Verteporfin, when activated by light, generates reactive oxygen species to selectively destroy abnormal neovascular tissue. The rationale for their combination is to enhance anti-neovascular effects: verteporfin targets the destruction of existing pathological vessels, while PTK787 aims to suppress subsequent neovascularization driven by VEGF upregulation post-PDT[1][4].

Brand names

visudyne

Other names

zd6474zd-6474zd 6474vatalanib